Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vanguard Total Bond Market Index Fund ETF (BND) vs Novo Nordisk A/S (NVO) Price & Performance

Vanguard Total Bond Market Index Fund ETFTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Vanguard Total Bond Market Index Fund ETF vs Novo Nordisk A/S — how do they compare? Vanguard Total Bond Market Index Fund ETF trades at $72.25, while Novo Nordisk A/S trades at $46.32 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while Vanguard Total Bond Market Index Fund ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, Vanguard Total Bond Market Index Fund ETF nearer its low. Which is the better fit depends on your goals.

BNDNVO
52-Week High
$75.17$63.98
52-Week Low
$72.15$35.29
Market Cap
$207.85B
Sector
Health
Enterprise Value
$222.55B
Dividend Yield
3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vanguard Total Bond Market Index Fund ETF

BND trades at $72.28, up 0.18% on the day, with a bearish technical signal driven by moving averages. Recent corporate actions include dividend payments of $0.25-$0.24, with the next scheduled for August 5, 2026. The ETF's neutral oscillators and flat support/resistance at $72 suggest consolidation. News highlights focus on bond ETF inflows and institutional positioning shifts.

The outlook remains cautious amid rising Treasury yields and inflation concerns. Opportunities lie in BND's role as a core fixed-income holding for diversification, but risks include interest rate sensitivity and macroeconomic volatility. Investor sentiment is mixed, balancing yield appeal against bond market headwinds.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.

Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Vanguard Total Bond Market Index Fund ETF

This index measures the performance of a wide spectrum of public, investment-grade, taxable, fixed income securities in the US, including government, corporate, and international dollar-denominated bonds, as well as mortgage-backed and asset-backed securities-all with maturities of more than 1 year. All of the fund's investments will be selected through the sampling process, and at least 80% of its assets will be invested in bonds held in the index.

Read more on BND

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO